Abstract：
Collagenous gastritis (CG) is a rare histopathological finding on gastric biopsies in children. It is associated with abdominal pain and iron deficiency anemia, usually not respondent to oral iron supplements. The aim of this study was to describe our experience in the management of pediatric patients with CG. Moreover, we propose to review the literature on this topic. We retrospectively reviewed all pediatric patients diagnosed with CG at our centre from January 2014 to January 2019. Three pediatric patients (2 F, mean age 12.3) were diagnosed with CG during the study period. Two presented with moderate and one with severe anemia. Symptoms were abdominal pain, asthenia and headache in two and asthenia and abdominal pain in one. All underwent upper and lower gastrointestinal endoscopy. All were firstly started with oral iron supplements with no benefit, principally due to poor compliance secondary to the worsening of the epigastric pain and proton pump inhibitor resistance. Therefore, they underwent ferric carboxymaltose (FCM) infusion with good clinical and laboratory response. Patients received a mean of two infusions/year, with stable hemoglobin levels and no adverse outcomes. Our review failed to identify a consistent response to specific treatments. Considering the apparent benign nature of the disease, symptomatic and supportive treatments are advisable. Iron deficiency anemia is largely present and therapy with oral iron supplements is not always successful. In our study, FCM infusion was effective in increasing the key blood indices in patients who poorly tolerated oral supplements.
摘要：
胶原性胃炎（CG）是儿童胃活检中罕见的组织病理学发现。它与腹痛和缺铁性贫血有关，通常对口服铁补充剂没有反应。这项研究的目的是描述我们在治疗小儿CG患者方面的经验。此外，我们建议回顾一下关于这个主题的文献。我们回顾性回顾了2014年1月至2019年1月在我们中心诊断为CG的所有儿科患者。三名儿科患者（2F，平均年龄12.3）在研究期间被诊断为CG。2例表现为中度贫血，1例表现为重度贫血。症状是腹痛,虚弱和头痛为两个，虚弱和腹痛为一个。所有患者均行上、下消化道内镜检查。所有这些都是首先从口服铁补充剂开始的，没有任何益处，主要是由于上腹痛和质子泵抑制剂抵抗恶化后的依从性差。因此,他们接受了羧基麦芽糖铁（FCM）输注，具有良好的临床和实验室反应。患者平均每年接受两次输液，血红蛋白水平稳定，无不良后果。我们的审查未能确定对特定治疗的一致反应。考虑到这种疾病的明显良性性质，对症和支持治疗是可取的。大量存在缺铁性贫血，口服铁补充剂治疗并不总是成功的。在我们的研究中,FCM输注可有效增加口服补充剂耐受性差的患者的关键血液指标。
